IOVANCE BIOTHERAPEUTICS INC

Phase‑I trial of Iovance Biotherapeutics’ EW‑001 CAR‑T begins in Australia, offering a mesothelioma treatment that may surpass standard options with early success in China.

Discover how Iovance Biotherapeutics’ cutting‑edge TIL cancer immunotherapy is shaping biotech investment—volatility, market potential, and growth insights.

Explore Iovance Biotherapeutics’ 2025 results, Amtagvi’s Canadian approval, plans to expand into Europe, Australia, and lung‑cancer trials, and market outlook.

Explore how Iovance Biotherapeutics gains a strategic edge in advanced melanoma after Replimune’s regulatory setback—insight into its TIL‑focused immunotherapy and market impact.

Investors eye Iovance Biotherapeutics: promising cancer immunotherapies but weak earnings, recent inducement grant, and stock volatility reveal challenges and potential.

Explore Iovance Biotherapeutics’ latest NASDAQ compliance win, volatile stock outlook, and cancer‑immunotherapy strategy—insights for investors.

Investors evaluate Iovance Biotherapeutics (IOV) amid a 35% dip, negative earnings, and a recent NASDAQ inducement grant, while watching its cancer immunotherapy progress.

Discover how Iovance Biotherapeutics leverages tumor‑infiltrating lymphocytes (TILs) to pioneer personalized cancer immunotherapies, market challenges, and future growth prospects.

Iovance Biotherapeutics Inc’s stock price plummeted to a new 52-week low, sparking concerns among investors and analysts, amidst a series of downgrades and lowered price targets.

Iovance Biotherapeutics’ stock has faced significant challenges in 2025, including a decline in Q1 performance, annual maintenance report discrepancies, and analyst downgrades, leading to a new 52-week low and market skepticism.